Amato M, Pasquier S, Carasso A, Von Muralt G
Department of Perinatal Medicine, University Clinic of Obstetrics and Gynecology, Berne, Switzerland.
Horm Res. 1988;29(1):27-30. doi: 10.1159/000180961.
Thirty-six preterm infants of less than 34 weeks of gestation with idiopathic respiratory distress syndrome (IRDS) were studied. Eighteen of them were treated with intravenous thyroxine (T4) and compared with 18 control prematures to evaluate the effect of postnatal T4 administration on the course of IRDS. After treatment, serum T4 levels were similar to those of healthy term infants. No statistically significant effect on mortality rate, duration of mechanical ventilation (p greater than 0.3), need of high oxygen environment (p greater than 0.05) and development of bronchopulmonary dysplasia (p greater than 0.2) was observed between the two groups. These observations show that postnatal use of T4 does not carry any benefit for preterm infants with IRDS.
对36例孕龄小于34周的特发性呼吸窘迫综合征（IRDS）早产儿进行了研究。其中18例接受静脉注射甲状腺素（T4）治疗，并与18例对照早产儿进行比较，以评估出生后给予T4对IRDS病程的影响。治疗后，血清T4水平与健康足月儿相似。两组之间在死亡率、机械通气时间（p>0.3）、高氧环境需求（p>0.05）和支气管肺发育不良发生率（p>0.2）方面未观察到统计学上的显著差异。这些观察结果表明，出生后使用T4对患有IRDS的早产儿没有任何益处。
